Cardiovascular Systems, Inc. (CSII)
Market Cap | 829.11M |
Revenue (ttm) | 239.84M |
Net Income (ttm) | -37.87M |
Shares Out | 41.96M |
EPS (ttm) | -0.96 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 455,843 |
Open | 19.74 |
Previous Close | 19.76 |
Day's Range | 19.70 - 19.77 |
52-Week Range | 12.26 - 23.47 |
Beta | 0.75 |
Analysts | Sell |
Price Target | 17.75 (-10.17%) |
Earnings Date | May 3, 2023 |
About CSII
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Co... [Read more]
Financial Performance
In 2022, CSII's revenue was $236.22 million, a decrease of -8.79% compared to the previous year's $258.97 million. Losses were -$36.93 million, 175.2% more than in 2021.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for CSII stock is "Sell." The 12-month stock price forecast is $17.75, which is a decrease of -10.17% from the latest price.
News

Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes
Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Cardiovascular Systems, Inc. - CSII
NEW YORK , Feb. 13, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...

CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. - CSII
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cardiovascular S...

Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss
With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.

SHAREHOLDER ALERT: Weiss Law Investigates Cardiovascular Systems, Inc.
NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cardiovascular Systems, Inc. ("Cardiovas...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Cardiovascular Systems, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - February 9, 2023) - Rigrodsky Law, P.A. is investigating Cardiovascular Systems, Inc. ("Cardiovascular") (NASDAQ: CSII) regarding possible breaches of fiduciary...

Why Is Cardiovascular Systems (CSII) Stock Up 48% Today?
Cardiovascular Systems (NASDAQ: CSII) stock is rising higher on Thursday following news that Abbott (NYSE: ABT) intends to acquire the company. That deal has Abbott offering to buy Cardiovascular Sy...

CSII STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Cardiovascular Systems, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cardiovascular Systems, Inc. (NASDAQ: CSII) to Abbott Laboratories for $20.00 per common ...

Cardiovascular Systems shares jump after deal to be bought by Abbott for $890 million
Cardiovascular Systems CSII, -1.99% shares rose 47% to $19.58 in early premarket trade after Abbott ABT, -1.60% agreed to buy the company for $890 million, or $20 per share. CSI is a leader in devices...

Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -33.33% and 2.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto...

Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients w...

Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays
Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.

Cardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (NASDAQ: CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, Feb...

Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

Cardiovascular Systems, Inc. Announces FDA 510(k) Submission of Innova Vascular, Inc.'s Thrombectomy System
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patien...

Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top
The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).

Cardiovascular Systems, Inc. to Participate in Two November Healthcare Conferences
ST. PAUL, Minn.

Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -12.50% and 0.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...

Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results
ST. PAUL, Minn.

Cardiovascular Systems (CSII) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Cardiovascular Systems (CSII) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems
ST. PAUL, Minn.

Cardiovascular Systems, Inc. to Host Earnings Conference Call on November 3, 2022
ST. PAUL, Minn.

Why Is Cardiovascular Systems (CSII) Down 18.9% Since Last Earnings Report?
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark
According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.

Cardiovascular Systems, Inc. Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS